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ABSTRACT
Introduction: Pruritus without visible
dermatoses may be the first manifestation of
hematological malignancies such as Hodgkin
disease, chronic lymphocytic leukemia and
mycosis fungoides (MF) and may precede the
definitive diagnosis by weeks to years.
Case Report: We present a case of ‘invisible’ MF
associated with chronic generalized pruritus in
an elderly patient.
Conclusion: Our case highlights the
importance of performing skin biopsies in
patients with chronic unexplained pruritus,
especially in the absence of cutaneous lesions.
This can prompt the clinician to consider
possible underlying malignancy, such as
‘invisible’ MF.
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INTRODUCTION
Pruritus is a prominent symptom of many skin
diseases and is also frequently present in
hematological malignancies such as Hodgkin
disease and occasionally in chronic
lymphocytic leukemia and mycosis fungoides
(MF) [1, 2]. Hepatobiliary malignancies are also
a rare cause. In some cases, pruritus without
visible dermatoses may be the first
manifestation of such diseases and may
precede the definitive diagnosis by weeks to
years [2].
We present a case of ‘invisible’ MF associated
with chronic generalized pruritus in an elderly
patient. Informed consent was obtained from
the patient for being included in the study.
CASE REPORT
An 80-year-old female presented with a
15-month history of persistent pruritus
affecting the arms, back, torso and anterior
lower limbs without any obvious dermatoses.
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She suffered periods of severe attacks of
pruritus, which occurred in waves
approximately every few weeks. There were no
clear-cut causes for the exacerbations, no
worsening with heat and she did not drink
alcohol. She was requiring fexofenadine and
diazepam each evening to get to sleep. She
denied fevers, night sweats or weight loss.
Her past medical history included non-insulin
dependent diabetes, hypertension,
hypercholesterolemia and glaucoma. She had
asthma and allergic rhinitis but denied any
history of eczema. There was no known history
of any drug allergies. Her regular medications
were amlodipine, indapamide, metformin and
simvastatin. She had been recently trialed off
gliclazide in case this medication had contributed
to her pruritus. She was taking regular salbutamol
for her asthma. The patient was also using the
following ocular drops for her glaucoma:
brimonidine, brinzolamide and bimatoprost.
Physical examination was grossly
unremarkable with no palpable nodes, no
palpable spleen and her skin looked generally
dry but normal in appearance with no visible
dermatoses present. With an atopic
background, it was thought the patient could
potentially have some subtle eczema and so was
treated with topical steroid ointment, 2%
menthol cream and an emollient.
Several weeks later, the pruritus had not
resolved and thus further investigations were
undertaken. Initial bloods demonstrated a
normal full blood count, liver function and
erythrocyte sedimentation rate, but she had
minor renal impairment. Uric acid was mildly
elevated at 0.44 mmol/L. Antibody studies
showed an intercellular substance antibody
titre of 40 (reference \10) and a basement
membrane antibody of \10 (reference \10).
Subsequent chest X-ray, abdominal ultrasound
and other blood tests were unrevealing.
As a result of these normal tests, two punch
biopsies from normal-appearing skin on the
abdomen were taken (Fig. 1). Histology showed
acanthosis with several collections of
lymphocytes in the basal layer forming small
Pautrier microabscesses (Fig. 2a).
Epidermotropism was also evident (Fig. 2b).
The superficial dermis showed fibrosis with a
perivascular infiltrate of lymphocytes, some of
which had hyperchromatic nuclei. On deeper
levels, some of the lymphocytes appeared large
and atypical with apoptotic lymphocytes also
present (Fig. 2c). Immunophenotyping showed
the majority of cells to be CD4 positive (Fig. 2d).
There was some loss of CD7 and only rare
CD30-positive cells. The immunofluorescence
was negative. These results were consistent with
a finding of CD4-positive MF.
Subsequent peripheral blood analysis
confirmed the presence of Sezary cells
(absolute number of circulating Sezary cells
was 30 per lL). Peripheral blood surface
Fig. 1 Clinical photograph demonstrating absence of
cutaneous lesions and site of biopsies
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markers detected an abnormal T cell population
with CD2, CD3, CD4 and CD5 positivity and
CD7, CD25 negativity. Human T-lymphotropic
virus type 1 and 2 antibodies were negative.
Bone marrow biopsy showed a very occasional
cell with Sezary morphology and normal
numbers of lymphocytes. T cell receptor (TCR)
gene rearrangement analysis revealed positive
TCR–Beta rearrangement but negative
TCR–Gamma rearrangement. The patient was
initially commenced on prednisone 10 mg daily
and methotrexate 5 mg weekly in combination
with folic acid. She was also commenced on
topical menthol ointment for the pruritus. The
methotrexate was titrated up to 20 mg weekly
for a trial of therapy for 8 weeks, while the
prednisone was weaned to 3 mg daily. This
resulted in some improvement in the pruritus.
Unfortunately, more recently she has developed
methotrexate-induced mucositis and raised
liver function tests, necessitating cessation of
the methotrexate.
DISCUSSION
Mycosis fungoides is the most common form of
cutaneous T cell lymphoma and represents
approximately 50% of all lymphomas arising
primarily in the skin [1, 2]. Cutaneous lesions
can be divided morphologically into patches,
plaques, and tumors, and this clinical
morphology is used to classify the disease into
three clinical stages accordingly [2]. The clinical
course can be protracted over years and
commonly manifests as generalized or localized
pruritus with associated dermatoses. However,
Fig. 2 a Histology showing Pautrier Microabscesses (H&E, 209). b Epidermotropism (H&E, 209). c Atypical
lymphocytes (H&E, 409). d Immunophenotyping showing CD4 positivity (209). H&E Hematoxylin and eosin stain
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very rarely MF can be clinically occult in the
setting ofpruritus as demonstrated in our case and
has been termed ‘invisible’ MF [3, 4]. It is the
significant association of generalized pruritus
with potential underlying malignancy that can
lead to diagnostic uncertainty and should
therefore prompt clinicians to perform
investigations to exclude systemic involvement.
‘Invisible’ MF has been previously reported
in four cases [3–6]. Two cases occurred as
incidental findings in asymptomatic patients
[3, 4]. The other case reports described two
patients in their 70s, who initially presented
with generalized long-standing pruritus with no
visible cutaneous lesions of MF [5, 6]. In our
case, the only manifestation of MF in the
patient was chronic pruritus and it was only
after taking biopsies from pruritic,
normal-appearing skin that a definitive
diagnosis could be made.
CONCLUSION
Our case highlights the importance of
performing skin biopsies in patients with
chronic unexplained pruritus, especially in the
absence of cutaneous lesions. In particular, more
attention should be given to elderly patients who
complain of persistent pruritus, which should
prompt the clinician to consider possible
underlying malignancy, such as ‘invisible’ MF.
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